Loading clinical trials...
Loading clinical trials...
An Exploratory Study of the Biologic Effects of Nivolumab and Ipilimumab Monotherapy and Nivolumab in Combination With Ipilimumab Treatment in Subjects With Advanced Melanoma (Unresectable or Metastatic)
Conditions
Interventions
Nivolumab
Ipilimumab
Locations
14
United States
Ucla
Los Angeles, California, United States
University Of Chicago
Chicago, Illinois, United States
Sidney kimmel comprehensive cancer center at johns hopkins
Lutherville, Maryland, United States
Beth Israel Deaconess Medical Center (BIDMC)
Boston, Massachusetts, United States
Dana Farber Cancer Institute
Boston, Massachusetts, United States
Massachusetts General Hospital
Boston, Massachusetts, United States
Start Date
September 27, 2012
Primary Completion Date
September 12, 2017
Completion Date
October 25, 2018
Last Updated
April 23, 2024
NCT05969860
NCT04693377
NCT06500455
NCT06066138
NCT05039801
NCT06264180
Lead Sponsor
Bristol-Myers Squibb
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions